Effect evaluation of medical insurance policy for hepatitis C DAA drugs based on patient survey

GUO Yijiao; GUO Zhaoting; HU Ming; FENG Haihuan

doi:10.6039/j.issn.1001-0408.2023.08.03

您当前的位置：

首页 >

文章列表页 >

Effect evaluation of medical insurance policy for hepatitis C DAA drugs based on patient survey

更新时间：2025-09-27

- Effect evaluation of medical insurance policy for hepatitis C DAA drugs based on patient survey
- ZHONGGUO YAOFANG Vol. 34, Issue 8, Pages: 907-910(2023)
- 作者机构：
  
  1.四川大学华西药学院，成都　610041
  2.四川大学华西医院医保办，成都　610041
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.08.03
  CLC： R95;R978.7;F840.684
- Received：27 October 2022，
  
  Revised：2023-03-14，
  
  Accepted：15 March 2023，
  
  Published：30 April 2023
- 稿件说明：
移动端阅览
郭一娇,郭昭廷,胡明,等.基于患者调查的丙型肝炎DAA药物医保政策实施效果评价[J].中国药房,2023,34(08):907-910.

GUO Yijiao,GUO Zhaoting,HU Ming,et al.Effect evaluation of medical insurance policy for hepatitis C DAA drugs based on patient survey[J].ZHONGGUO YAOFANG,2023,34(08):907-910.
郭一娇,郭昭廷,胡明,等.基于患者调查的丙型肝炎DAA药物医保政策实施效果评价[J].中国药房,2023,34(08):907-910. DOI： 10.6039/j.issn.1001-0408.2023.08.03.

GUO Yijiao,GUO Zhaoting,HU Ming,et al.Effect evaluation of medical insurance policy for hepatitis C DAA drugs based on patient survey[J].ZHONGGUO YAOFANG,2023,34(08):907-910. DOI： 10.6039/j.issn.1001-0408.2023.08.03.

摘要

目的

为丙型肝炎（以下简称“丙肝”）防治工作的开展以及直接抗病毒（DAA）药物医保支付政策的制定和完善提供参考。

方法

采用问卷调研的方法对2019－2020年在四川省内某三甲医院进行丙肝治疗并享受成都市丙肝医保政策的患者进行调研，比较DAA药物纳入医保目录前后患者的丙肝治疗情况及对DAA药物医保政策的满意度。

结果

对644名患者进行了调查研究，有效应答人数共计203例。在治疗方案方面，虽然2019年和2020年就诊的患者在用药方案上存在明显差异（

＜0.05），但绝大多数患者在疗程内获得治愈（200例，98.52%），且无明显不良反应发生（193例，95.07%）；在经济负担方面，2020年接受DAA药物治疗的患者其自付费用和经济负担明显低于2019年就诊的患者（

＜0.05）；在患者服务方面，78.82%的患者接受了医保定点医疗机构提供的专家咨询服务，但仍有9.85%的患者未接受医院提供的任何患者服务。在门诊报销政策的满意度方面，2020年就诊的患者在对于DAA药物医保政策的整体满意度（95.37%）明显高于2019年就诊的患者（81.05%）（

＜0.05）。

结论

受访患者使用DAA药物治疗丙肝的效果较好，且对丙肝DAA药物医保政策表示满意，但定点医疗机构在患者服务规范化管理方面还存在不足。

Abstract

OBJECTIVE

To provide reference for the prevention and treatment of hepatitis C and the formulation and improvement of medical insurance payment policy for direct-acting antiviral （DAA） drugs.

METHODS

An questionnaire survey was conducted among the patients who received hepatitis C treatment in a third-grade class-A hospital in Sichuan province from 2019 to 2020 and enjoyed Chengdu medical insurance policy. The patients’ hepatitis C treatment and satisfaction with the medical insurance policy for DAA drugs were compared before and after DAA drugs were included in the medical insurance list.

RESULTS

A total of 203 patients effectively responded among 644 investigated patients. In terms of treatment plans， although there were significant differences in the treatment plan between patients who saw a doctor in 2019 and 2020 （

＜0.05）， the vast majority of patients were cured within the course of treatment （200 cases， 98.52%）， and there were no obvious adverse reactions （193 cases， 95.07%）. In terms of economic burden， the out-of-pocket costs and economic burden of patients treated with DAA drugs in 2020 were significantly lower than those treated with DAA drugs in 2019 （

＜0.05）； in terms of patient services， 78.82% of patients received expert consultation services from designated medical institutions， but 9.85% of patients still did not receive any patient services provided by the hospital. In terms of satisfaction with outpatient reimbursement policy， the overall satisfaction of patients who saw a doctor in 2020 （95.37%） was significantly higher than those who saw a doctor in 2019 （81.05%）（

＜0.05）.

CONCLUSIONS

The surveyed patients with hepatitis C obtain good efficacy after DAA drugs treatment， and are satisfied with the medical insurance policy of DAA drugs， but the standardized management of patient services in designated medical institutions is insufficient.

关键词

Keywords

references

王贵强魏来 . 健康中国2030消除丙肝威胁行动白皮书 [EB/OL ] .[ 2022-11-15 ] . https：//www.waitang.com/report/365548.html https://www.waitang.com/report/365548.html .

付露阳，马爱霞 . 盐酸达拉他韦联合阿舒瑞韦治疗慢性丙型肝炎的经济学评价 [J ] . 中国药物经济学， 2018 ， 13 （ 6 ）： 5 - 9 .

OMATA M ， KANDA T ， WEI L ， et al . APASL consensus statements and recommendation on treatment of hepatitis C [J ] . Hepatol Int ， 2016 ， 10 （ 5 ）： 702 - 726 .

European Association for the Study of the Liver . EASL recommendations on treatment of hepatitis C：2015 [J ] . J Hepatol ， 2015 ， 63 （ 1 ）： 199 - 236 .

汤正明 . 探讨丙肝病毒直接抗病毒药物治疗慢性丙型肝炎的疗效 [J ] . 医学食疗与健康， 2021 ， 19 （ 8 ）： 60 - 61 .

成都市人力资源和社会保障局 . 关于对丙型肝炎门诊医疗费实施医疗保险分类付费有关问题的通知 [EB/OL ] .（ 2018-11-05 ）[ 2022-11-13 ] . http：//cdhrss.chengdu.gov.cn/cdrsj/c109727/2019-01/08/content_6ba0a2798e6a4d4da1f-7effc0a09a403.shtml http://cdhrss.chengdu.gov.cn/cdrsj/c109727/2019-01/08/content_6ba0a2798e6a4d4da1f-7effc0a09a403.shtml .

成都市医疗保障局，成都市人力资源和社会保障局 . 关于转发《关于将2019年谈判药品纳入<国家基本医疗保险、工伤保险和生育保险药品目录>乙类支付范围》的通知 [EB/OL ] .（ 2019-12-31 ）[ 2023-01-15 ] . http：//cdyb.chengdu.gov.cn/ylbzj/c128998/2020-01/15/content_f7fa02002916-47c18e967a7cebb5a22c.shtml http://cdyb.chengdu.gov.cn/ylbzj/c128998/2020-01/15/content_f7fa02002916-47c18e967a7cebb5a22c.shtml .

LOZANO L M ， GARCÍA-CUETO E ， MUÑIZ J . Effect of the number of response categories on the reliability and validity of rating scales [J ] . Methodology ， 2008 ， 4 （ 2 ）： 73 - 79 .

杨毅，田侃 . 基于医患双方的公立医院声誉评价指标体系研究 [J ] . 中国全科医学， 2017 ， 20 （ 6 ）： 699 - 705，710 .

孙丹青，崔楠，丁磊，等 . 基于双因素理论的三级公立医院医师离职倾向评价体系的构建与可行性研究 [J ] . 中国医院， 2022 ， 26 （ 9 ）： 73 - 76 .

贺娜，郝帅，冯巩，等 . 医院内丙型肝炎诊治现状对院内消除策略的影响因素分析 [J ] . 中华肝脏病杂志， 2021 ， 29 （ 11 ）： 1053 - 1058 .

WHO . Global health sector strategy on viral hepatitis 2016-2021，towards ending viral hepatitis [R ] . Geneva ： World Health Organization ， 2016 ．

Views

283

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comparison of the efficacy of remimazolam and propofol in the induction and maintenance of general anesthesia in elderly patients undergoing thoracoscopic lobectomy

Investigation of the mode of pharmacist participating in multi-disciplinary diagnosis and treatment and effect evaluation

Evaluation of implementation situation of prescription circulation service in medical institutions based on patient KAP survey

我院抗菌药物专项整治活动干预措施及效果分析

芜湖市公立医院实施药品“零差率”政策的效果分析

Related Author

PAN Pengfei

YANG Ping

LI Junjie

YANG Jinqiu

HUANG Yu

HU Juan

LIU Chun

LIU Fang

Related Institution

Postgraduate Training Base of Chongqing University Three Gorges Hospital， Jinzhou Medical University

Anesthesia Operation Center， Chongqing University Three Gorges Hospital

Dept. of Critical Care Medicine， Chongqing University Three Gorges Hospital

Dept. of Pharmacy， the Third Hospital of Peking University

Dept. of Pharmacy， the First Hospital of Shanxi Medical University

⁰